Nanobots are a professional class of nanomaterials that specialize in operating at the nanolevel—typically between 0.5 and 3 µm—by having the ability to travel, perceive, communicate, and engage with cell and tissue structures in high specificity through programmability. Passive nanomaterials are opposed by the reality that nanobots are programmable and autonomous and can sense and react to the environment. In the field of medicine, they can be guided or programmed to perform complex operations such as targeted drug delivery, biosensing, and microsurgery. The nanotechnology theory was initially developed in 1867 as James Clerk Maxwell’s thought experiment “Maxwell's demon,” while the idea of nanorobotics was first envisioned by physicist Richard Feynman in 1959. Actual development began in the early 21st century with Professor Toshio Fukuda, who created systems for single-cell operation. As Giri et al. (2021) note, “the emergence of biomolecular science and modern manufacturing methods has enabled the creation of autonomous, programmable nanobots for in vivo use” (para. 7). 

​

One of the most thrilling possible medical applications of nanobots is precision cancer treatment. Conventional treatments such as chemotherapy destroy healthy and cancer cells alike, but nanobots can be engineered to target and kill only cancer cells with minimal side effects. Kong et al. (2023) highlight that “nanobots enable the assembly and deployment of therapeutic agents with precise targeting, allowing for the destruction of cancer cells while minimizing collateral damage to healthy tissues” (para. 1). Luz et al. (2016) similarly highlight the role of biotechnology and molecular biology in designing nanorobots for precision targeting in cancer therapy.

 

There are still major technical challenges, however. Giri et al. (2021) comment that actuating and sensing nanobots in complex biological environments are significant challenges for clinical translation. Likewise, Kong et al. (2023) comment on limitations in in vivo power source integrity, localization, and navigation. These papers as a whole demonstrate the enormous capability of nanobot technology for medicine as well as ongoing engineering challenges that must be addressed before it can be implemented clinically. 

Nanobots are also capable of traveling along narrow blood vessels and fragile tissues, and thus, they can be used for tissue sampling, microsurgery, and targeted imaging. Their tiny size and strategic design allow them to perform minimally invasive procedures such as declogging arteries by thrombectomy or restoring blood flow via recanalization surgery. 

​

Another advantage is their ability to function independently at the microlevel. Unlike most nanomaterials, which rely on passive diffusion, nanobots can be powered by magnetic fields, light, ultrasound, or chemical reactions, which will allow them to travel throughout the body autonomously and carry out specific tasks. Others can generate power from natural bodily chemicals like glucose or urea, using the human body itself as a power source. 

​

Building a nanobot is no easy task. These devices are made of flexible and biocompatible materials so they can safely operate inside the body. Their shapes vary—spheres, tubes, and helices are the most common—depending on what job they need to perform. Nanobots often rely on self-assembly techniques, where materials like polymers, metals, or biological molecules organize themselves into the desired structure. As described by Wang et al., “biohybrid micro/nanorobots combine living cells or organisms with synthetic components, leveraging natural motility and energy sources to enhance medical functionality” (2020, para. 5). For example, single-stranded DNA can be folded into a 3D nanobot that releases drugs when it detects a cancer biomarker. Similarly, viral capsids, which are naturally strong and stable, can be modified to act as nanobot shells that release medicine when they bind to specific receptors on cells. New fabrication methods such as 3D printing, rolled-up lithography, and glancing angle deposition are now helping scientists design more complex nanobots. At the same time, biodegradability is a key goal—once a nanobot finishes its job, it can safely dissolve without any need for removal surgery. A 2024 review emphasizes, “the fabrication of biocompatible and biodegradable nanobots is essential for ensuring safe operation within the human body” (Bahaar et al., 2024, pg. 2). 

​

One of the most significant nanobot technology challenges is discovering reliable sources of power for nanobots operating inside the human body. According to Giri et al. (2021), there are numerous technical obstacles that are significant bottlenecks for clinical translation, and among them are powering, sensing, and actuating nanobots in complex biological environments. These are because powering systems need to be not only compatible in the biological environment but also effective at the nanoscale. Similarly, Kong et al. (2023) discuss the state of the art in in vivo experiments and note that the functioning of medical nanobots relies on overcoming navigation, localization, and power supply reliability problems. According to their review, research is ongoing towards the design of self-powered or remotely powered nanobots that will efficiently function in physiological environments. Together, these research studies underscore the fact that developments on control and power systems for nanobots remain essential to progress from experimental concepts to real-world clinical applications. 

​

While the field is still emerging, in vivo experiments have already shown nanobots can improve drug delivery, improve tissue penetration, and keep therapeutic payloads longer than traditional methods. Nanotechnology is one of the most hopeful fields of contemporary medicine. If scientists manage to overcome the challenges of energy, design, and biocompatibility, nanobots may transform how we treat illnesses.

​

​

​

References 

​

Bahaar, H., Kumar, B. S., Reddy, S. G., Guo, Z. (2024). From Concept to Creation: Micro/Nanobot Technology from Fabrication to Biomedical Applications. Engineered Science Publisher. Retrieved from https://www.espublisher.com/journals/articledetails/1346 

Giri, G., Maddahi, Y., & Zareinia, K. (2021). A brief review on challenges in design and development of nanorobots for medical applications. Applied Sciences. Retrieved from https://www.mdpi.com/2076-3417/11/21/10385 

Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K.C. (2023). Advances of medical nanorobots for future cancer treatments. Journal of Hematology & Oncology. Retrieved from https://link.springer.com/article/10.1186/s13045-023-01463-z 

Luz, G. V. da Silva, Barros, K. V. G., et al. (2016). Nanorobotics in drug delivery systems for treatment of cancer: a review. Journal of Materials Science: Materials in Medicine. Retrieved from 

https://pdfs.semanticscholar.org/0c8f/53f0cda35fe33d7aad7ec84e8dc3a4bb3bc0.pdf

Sanaz Aliakbarzadeh, Majid Abdouss, Fathi-karkan, S., Abbas Rahdar, Pejman Zarbanooei, Kang, M., & Pandey, S. (2024). Micro-Surgeons and Nano-Pharmacists: The Future of Healthcare with Medical Nanorobots. Journal of Drug Delivery Science and Technology, 106410–106410. https://doi.org/10.1016/j.jddst.2024.106410 

Wang, B., Kostarelos, K., Nelson, B. J. (2021). Trends in micro‐/nanorobotics: materials development, actuation, localization, and system integration for biomedical applications. Advanced Materials. Retrieved from https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adma.202002047